Recombinant interferon-alpha2b poly(lactic-co-glycolic acid) microspheres: pharmacokinetics-pharmacodynamics study in rhesus monkeys following intramuscular administration

Zhang, Yongming; Yang, Fan; Yang, Yi-qun; Song, Feifei; Xu, Anlong

doi:10.1111/j.1745-7254.2008.00881.x

Cited by 20 publications

(8 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar PLGA particles also show promise as a delivery vehicle for proteins [5,6], siRNA [7], and for presenting antigens to dendritic cells for vaccination [8-10]. It is also becoming clear that PLGA particles offer considerable flexibility in choosing a route of delivery because they have proven to be effective when injected intramuscularly [11,12], when delivered via inhalation [13-15], and recent results indicate that they also have promise for oral delivery of drugs and antigens [16-19]. …”

Section: Introductionmentioning

confidence: 99%

Fabrication of PLGA nanoparticles with a fluidic nanoprecipitation system

Xie

Smith

2010

J Nanobiotechnol

View full text Add to dashboard Cite

Particle size is a key feature in determining performance of nanoparticles as drug carriers because it influences circulating half-life, cellular uptake and biodistribution. Because the size of particles has such a major impact on their performance, the uniformity of the particle population is also a significant factor. Particles comprised of the polymer poly(lactic-co-glycolic acid) (PLGA) are widely studied as therapeutic delivery vehicles because they are biodegradable and biocompatible. In fact, microparticles comprised of PLGA are already approved for drug delivery. Unfortunately, PLGA nanoparticles prepared by conventional methods usually lack uniformity. We developed a novel Fluidic NanoPrecipitation System (FNPS) to fabricate highly uniform PLGA particles. Several parameters can be fine-tuned to generate particles of various sizes.

show abstract

Section: Introductionmentioning

confidence: 99%

Fabrication of PLGA nanoparticles with a fluidic nanoprecipitation system

Xie

Smith

2010

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…Thus, Sáez and coworkers encapsulated the protein in PLGA microparticles, with no changes in its physicochemical and biological characteristics during its release in vitro [98]. Zhang and coworkers fabricated PLGA microparticles, observing an increase in the residence time of IFNα in serum up to 18 days and a sustained release of up to 12 days in studies in rhesus monkeys [99]. The alginate-chitosan microspheres of Zheng and coworkers also manifested a 4-fold increase in the half-life time of IFNα.…”

Section: Ifnαmentioning

confidence: 99%

“…The microencapsulation process achieved less than 60% encapsulation efficiency in several formulations [101,113], while a reduction in biological activity was observed in some cases [93,100,106]. In other formulations, the drug was released abruptly or incompletely [94,99,130]. For instance, a study conducted by Saez et al in 2013 showed that IFNα release in PLGA microparticles did not exceed 75% [131].…”

Section: Ifn γmentioning

confidence: 99%

Forms and Methods for Interferon's Encapsulation

Ramos¹,

Villacis²,

Vispo³

et al. 2021

Preprint

View full text Add to dashboard Cite

Interferons (IFNs) are cytokines involved in the immune response that act on innate and adaptive immunity. These proteins are natural cell-signaling glycoproteins expressed in response to viral infections, tumors, and biological inducers and constitute the first line of defense of vertebrates against infectious agents. They have been marketed for more than 30 years with considerable impact on the global therapeutic protein market thanks to their diversity in terms of biological activities. They have been used as single agents or with combination treatment regimens, demonstrating promising clinical results, resulting in 22 different formulations approved by regulatory agencies. The 163 clinical trials with currently active IFNs reinforce their importance as therapeutics for human health. However, their application has presented difficulties due to the molecules’ size, sensitivity to degradation, and rapid elimination from the bloodstream. For some years now, work has been underway to obtain new drug delivery systems to provide adequate therapeutic concentrations for these cytokines, decrease their toxicity and prolong their half-life in the circulation. Although different research groups have presented various formulations that encapsulate IFNs, to date, there is no formulation approved for use in humans. The current review exhibits an updated summary of all encapsulation forms presented in the scientific literature for these cytokines IFNα, IFNß, and IFNγ, from the year 1996 to the year 2021, considering parameters such as: encapsulating matrix, route of administration, and encapsulation.

show abstract

“…However, there was no plasma IFN-α in BDM-hIFN-α-injected rats at 8 h post-injection. It has been previously demonstrated that plasma concentrations of IFN-2αb reached a peak at 7.5 h in rhesus monkeys injected with IFN-2αb-loaded PLGA microspheres, and the serum residence time of IFN-2αb in the PLGA microspheres was about 4 days [30]. The early peak (10 min) of plasma concentrations of IFN-α in BDM-IFNα-injected rats seen in this study might be due to the fact that IFN-α was not completely encapsulated into BDM and/or it was merely contact on the surface of microspheres, thereby leading to such an early burst release.…”

Section: Branched Dextran Microspheres Of Soluble Ifn-α and Its Activmentioning

confidence: 99%

Preparation of Branched Dextran Microspheres of Soluble Interferon Interferon-alpha and its Activity In Vitro and In Vivo

Hong

Jo²,

Yeon³

et al. 2011

J. Microbiol. Biotechnol.

View full text Add to dashboard Cite

The study objective was to prepare biodegradable branched dextran microspheres encapsulated with His-tagged interferon-alpha (BDM-hIFN-α) and evaluate its activity in vitro and in vivo. The glycidyl methacrylate derivatized dextrans (Dex-GMA) as precursor was primarily synthesized by substituting hydroxyl groups of either the branched or linear type of dextran with GMA. Dex-GMA microspheres loaded with hIFN-α was then prepared by the water-inwater emulsion technique. In vitro release and Western blotting experiments demonstrated the retained activity of hIFN-α released from branched dextran microspheres at 24 h by inducing phosphorylation of signal transducer and activator transcription-1 (STAT-1), a downstream effector of IFN-α, in HepG2 cells. Animal data further revealed a peak of plasma levels of IFN-α in rats injected intravenously with BDM-hIFN-α at 10 min post-injection, but a sharp decline at 2 h. High plasma levels of neopterin, a plasma protein induced by IFN-α, were also detected in rats injected with BDM-hIFN-α at 10 min post-injection. Notably, plasma levels of neopterin remained high at 4 h, but largely declined thereafter.

show abstract

Recombinant interferon-alpha2b poly(lactic-co-glycolic acid) microspheres: pharmacokinetics-pharmacodynamics study in rhesus monkeys following intramuscular administration

Cited by 20 publications

References 9 publications

Fabrication of PLGA nanoparticles with a fluidic nanoprecipitation system

Fabrication of PLGA nanoparticles with a fluidic nanoprecipitation system

Forms and Methods for Interferon's Encapsulation

Preparation of Branched Dextran Microspheres of Soluble Interferon Interferon-alpha and its Activity In Vitro and In Vivo

Contact Info

Product

Resources

About